Philip Mease

Philip Mease

UNVERIFIED PROFILE

Are you Philip Mease?   Register this Author

Register author
Philip Mease

Philip Mease

Publications by authors named "Philip Mease"

Are you Philip Mease?   Register this Author

100Publications

3354Reads

32Profile Views

Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018.

J Rheumatol 2019 Oct 1;46(10):1355-1359. Epub 2019 Apr 1.

From the Department of Epidemiology and Biostatistics, Amsterdam University Medical Centre (VUmc); VUmc, Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam; Department of General Practice, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; Comprehensive Pain Center, University Hospital Carl Gustav Carus Dresden, Medical Faculty of the Technical University Dresden, Dresden, Germany; CREATE Centre, Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds; Versus Arthritis, Patron Her Royal Highness The Duchess of Cornwall, Chesterfield; MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, UK; Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; The Rheumatology Research Unit, Department of Rheumatology, Odense University Hospital; Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark; Dragon Claw (Website for patients with rheumatic disease), New South Wales, Australia; Bingo and Fundraising Promotions, Mal Atwell Leisure Group, Willetton, Australia; SDG LLC, Cambridge, Massachusetts; Medicine Service, VA Medical Center; Departments of Medicine and Epidemiology at the Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, Alabama; Department of Anesthesiology and Pain Medicine, University of Washington; Rheumatology Research Swedish-Providence-St. Joseph Health Systems; University of Washington School of Medicine, Seattle, Washington, USA; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181099DOI Listing
October 2019

Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria.

Scand J Pain 2019 Oct 9. Epub 2019 Oct 9.

National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/sjpain-2019-0054DOI Listing
October 2019

Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.

J Rheumatol 2019 Oct 15. Epub 2019 Oct 15.

From the Johns Hopkins University School of Medicine, Baltimore, MD, USA; University of Glasgow, Glasgow, United Kingdom; University of Oxford, Oxford, United Kingdom; Cleveland Clinic, Cleveland, OH, USA; Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada; Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Pitié Salpêtrière Hospital, AP-HP, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. This study is funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ. Support for third-party writing assistance for this manuscript, furnished by Eric Deutsch, PhD, CMPP, of Health Interactions, Inc, was provided by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Conflicts of Interest: A-M. Orbai has received grant support from AbbVie, Celgene, Horizon, Janssen, Lilly, and Novartis, consulting fees from Janssen, Lilly, Novartis, Pfizer, and UCB, is a Jerome L Greene Foundation Scholar and is supported in part by a research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Secukinumab Improves GRAPPA-OMERACT Domains Institutes of Health (NIH) under award number P30- AR070254 (Core B), a Rheumatology Research Foundation Scientist Development Award, and a Staurulakis Family Discovery Award. I. B. McInnes has received grant support from Bristol-Myers Squibb, Celgene, Janssen, and UCB, and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, and UCB. L. C. Coates has received grant support from AbbVie, Celgene, Novartis, and Pfizer, consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, MSD, Novartis, Pfizer, Prothena, Sun Pharma, and UCB, and speakers bureau fees from AbbVie, Celgene, Janssen, Lilly, Novartis, and UCB. M. E. Husni has received grant support from Janssen. D. D. Gladman has received grant support from AbbVie, Amgen, Celgene, Lilly, Novartis, Pfizer, and UCB, and consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. L. Gossec has received grant support from Bristol-Myers Squibb, Lilly, Pfizer, and UCB, and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, and UCB. L. Pricop, O. Chambenoit, and X. Meng are employees and stockholders of Novartis. P. J. Mease has received research grants from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun Pharma, and UCB; and speakers bureau fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, and UCB. A.-M. Orbai, MD, MHS, Johns Hopkins University School of Medicine, Baltimore, MD, USA; I. B. McInnes, MD, PhD, University of Glasgow, Glasgow, United Kingdom; L. C. Coates, MBChB, PhD, University of Oxford, Oxford, United Kingdom; M. E. Husni, MD, MPH, Cleveland Clinic, Cleveland, OH, USA; D. D. Gladman, MD, FRCPC, Toronto Western Research Institute and University of Toronto, Toronto, ON, Canada; L. Gossec, MD, PhD, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France, and Pitié Salpêtrière Hospital, Secukinumab Improves GRAPPA-OMERACT Domains AP-HP, Paris, France; L. Pricop, MD, O. Chambenoit, PhD, X. Meng, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; P. J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Address correspondence and requests for reprints to: Ana-Maria Orbai, MD, MHS (ORCID iD: 0000-0001-8644-8567), Assistant Professor of Medicine, Johns Hopkins University School of Medicine, Division of Rheumatology, MFL Center Tower, Suite 4100, 5200 Eastern Ave, Baltimore, MD 21224; Tel: 410-550-8231; Fax: 410-550-2072; Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190507DOI Listing
October 2019

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.

Rheumatol Ther 2019 Sep 28;6(3):435-450. Epub 2019 Jun 28.

NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40744-019-0165-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702662PMC
September 2019

Measurement properties of the minimal disease activity criteria for psoriatic arthritis.

RMD Open 2019 6;5(2):e001002. Epub 2019 Sep 6.

School of Medicine, Swedish Medical Center and University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2019-001002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744081PMC
September 2019

Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population.

Patient Prefer Adherence 2019 13;13:1545-1556. Epub 2019 Sep 13.

Department of Internal Medicine and Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
https://www.dovepress.com/participation-in-an-innovative-pat
Publisher Site
http://dx.doi.org/10.2147/PPA.S215037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750846PMC
September 2019

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

J Rheumatol 2019 Aug 15;46(8):990-995. Epub 2018 Dec 15.

From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore; Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Division of Immunology, Stanford University, Palo Alto, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Global Patient Outcomes and Real World Evidence, Eli Lilly and Co., Indianapolis, Indiana; University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Royal National Hospital for Rheumatic Diseases, Bath; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Sorbonne Université; Rheumatology Department, Pitié Salpêtrière Hospital, AP-HP, Paris, France; VU Medical Centre, Amsterdam, the Netherlands; Global Medical Affairs, Pfizer Inc., Montreal, Quebec; Clinical Epidemiology Program, Ottawa Hospital Research Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, Institute for Health Policy Management and Evaluation, University of Toronto; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571063PMC
August 2019

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

J Rheumatol 2019 Aug 15;46(8):996-1005. Epub 2019 Feb 15.

From the Division of Rheumatology, Department of Medicine, and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Amgen Inc., Thousand Oaks, California; Swedish-Providence-St. John's Health Systems and University of Washington, Seattle, Washington; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore; University of Leeds, Leeds; University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; Department of Medicine, University of Toronto, Women's College Hospital; Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto; Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario; Pfizer Inc., Montreal, Quebec, Canada; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre, Amsterdam, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Ireland; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.181089DOI Listing
August 2019

Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.

J Rheumatol Suppl 2019 Jun;95:11-19

From the Rheumatology Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals NHS Foundation Trust, Bradford, UK; Department of Medicine, Division of Rheumatology, University of Toronto; Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Swedish Medical Center/Providence-St. Joseph Health, Seattle, Washington; University of Southern California, Los Angeles, California; University of Utah, Salt Lake City, Utah; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Conway Institute for Biomolecular Research, University College Dublin; Our Lady's Hospice and Care Services; Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Department of Medical Humanities, Amsterdam University Medical Center, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190118DOI Listing
June 2019

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

J Rheumatol Suppl 2019 Jun;95:33-37

From the Duke-NUS Medical School, Singapore; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Dermatology, University of Utah, Salt Lake City, Utah; Kezar Life Sciences, San Francisco; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, UK; Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam, the Netherlands; Women's College Research Institute, Women's College Hospital, Department of Medicine, University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190122DOI Listing
June 2019

GRAPPA 2018 Project Report.

J Rheumatol Suppl 2019 Jun;95:54-57

From Kezar Life Sciences, San Francisco, California; Duke University School of Medicine, Durham, North Carolina, USA; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Toronto; Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; UK National Institute for Health Research (NIHR), Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of California at San Diego, La Jolla, California, USA; University of Alberta, Edmonton, Alberta, Canada; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington, USA; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.190121DOI Listing
June 2019

Measuring Psoriatic Arthritis Symptoms, A Core Domain in Psoriasis Clinical Trials.

J Am Acad Dermatol 2019 Jun 1. Epub 2019 Jun 1.

Department of Dermatology and Department of Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.05.075DOI Listing
June 2019

Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.

Authors:
Philip Mease

Curr Rheumatol Rep 2019 Jun 6;21(7):35. Epub 2019 Jun 6.

Rheumatology Research, Swedish Medical Center/Providence-St. Joseph Health, University of Washington School of Medicine, 601 Broadway Suite 600, Seattle, WA, 98122, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11926-019-0830-0DOI Listing
June 2019

Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.

J Rheumatol 2019 May 15;46(5):475-482. Epub 2019 Jan 15.

From the University of Pennsylvania, Philadelphia, Pennsylvania; Corrona Research Foundation; New York University Hospital for Joint Diseases, New York, New York; University of Alabama at Birmingham, Birmingham, Alabama; University of Massachusetts, Worcester; Brigham and Women's Hospital, Boston, Massachusetts; University of California San Diego, San Diego, California; Albany Medical College, Albany, New York; Swedish Medical Center; University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.171034
Publisher Site
http://dx.doi.org/10.3899/jrheum.171034DOI Listing
May 2019

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

J Comp Eff Res 2019 May 26;8(7):497-510. Epub 2019 Feb 26.

CREATE Centre, Section of Rheumatology - Division of Infection & Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park Campus, Cardiff, CF14 4XN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2018-0141DOI Listing
May 2019

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.

Arthritis Res Ther 2019 May 10;21(1):118. Epub 2019 May 10.

Rheumatology Clinical Research Division, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-019-1901-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509758PMC
May 2019

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.

Arthritis Care Res (Hoboken) 2019 Mar 12;71(3):367-378. Epub 2019 Feb 12.

University of Queensland Brisbane, Rheumatology Research Unit Sunshine Coast, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/acr.23738
Publisher Site
http://dx.doi.org/10.1002/acr.23738DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593968PMC
March 2019

Ustekinumab Fails to Show Efficacy in a Phase III Axial Spondyloarthritis Program: The Importance of Negative Results.

Authors:
Philip Mease

Arthritis Rheumatol 2019 02 2;71(2):179-181. Epub 2019 Jan 2.

Swedish Medical Center and University of Washington Medical School, Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.40759DOI Listing
February 2019

Anti-Inflammatory Effects of Intra-Articular Hyaluronic Acid: A Systematic Review.

Cartilage 2019 01 11;10(1):43-52. Epub 2018 Feb 11.

5 Swedish-Providence-St. Joseph's Health Systems, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1947603517749919DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376563PMC
January 2019

Functional impairment measurement in psoriatic arthritis: Importance and challenges.

Semin Arthritis Rheum 2018 12 23;48(3):436-448. Epub 2018 May 23.

University of Toronto and Toronto Western Hospital, 399 Bathurst Street 1E-410B, Toronto, ON, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2018.05.010DOI Listing
December 2018

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry.

Arthritis Care Res (Hoboken) 2018 11 8;70(11):1661-1670. Epub 2018 Oct 8.

Corrona, LLC, Southborough, Massachusetts and New York University School of Medicine, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282817PMC
November 2018

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Rheumatology (Oxford) 2018 10;57(10):1777-1788

Division of Rheumatology, Department of Medicine, University of Toronto, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152421PMC
October 2018

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

J Rheumatol 2018 10 1;45(10):1389-1396. Epub 2018 Jul 1.

From the Swedish Medical Center and University of Washington, Seattle, Washington; Novartis Pharmaceuticals Corp., East Hanover, New Jersey; Corrona LLC, Waltham, Massachusetts; University of California San Diego, La Jolla, California; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester; New York University School of Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171094DOI Listing
October 2018

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

J Am Acad Dermatol 2018 Sep 17;79(3):593-595. Epub 2018 Mar 17.

Department of Rheumatology Research, Swedish-Providence-St. Joseph Health Systems and University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.008DOI Listing
September 2018

Classification and Outcome Measures for Psoriatic Arthritis.

Front Med (Lausanne) 2018 6;5:246. Epub 2018 Sep 6.

Division of Rheumatology and Krembil Research Institute, University Health Network, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2018.00246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135872PMC
September 2018

Remission in psoriatic arthritis-where are we now?

Rheumatology (Oxford) 2018 08;57(8):1321-1331

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kex344DOI Listing
August 2018

Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.

Arthritis Care Res (Hoboken) 2018 08 29;70(8):1206-1217. Epub 2018 May 29.

Parker Institute, Copenhagen University Hospital, and Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acr.23455DOI Listing
August 2018

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study.

J Rheumatol 2018 08 15;45(9):1256-1262. Epub 2018 Jun 15.

From the Department of Medical Sciences, Policlinico of the University of Cagliari; Rheumatology Unit, and Department of Public Health, University of Cagliari, Cagliari; Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera; Rheumatology Research Unit, Department of Clinical and Experimental Medicine, University "Federico II," Naples; Department of Rheumatology, ASST Gaetano Pini-Centro Traumatologico Ortopedico (CTO), Milan; Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Modena and Reggio Emilia; Dipartimento di Medicina e Scienze della Salute, Università degli Studi del Molise, Campobasso, Italy; University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Academic Medical Center/University of Amsterdam; Amsterdam Rheumatology and Immunology Center Reade, Amsterdam, the Netherlands; Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand; Medizinische Klinik III mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nuernberg, Erlangen, Germany; Sector of Dermatology, HUCFF School of Medicine, Federal University of Rio de Janeiro and Sector of Dermatology, HUPE School of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil; Spondyloarthritis Program, Johns Hopkins University, School of Medicine, Baltimore, Maryland; Swedish Medical Centre and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Semmelweis University, Budapest, Hungary; Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.171183DOI Listing
August 2018

Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study.

Ann Rheum Dis 2018 07 3;77(7):1091-1093. Epub 2017 Jul 3.

Department of Rheumatology, University Pierre et Marie Curie Paris 6 HÃ'pital Cochin, AP-HP, INSERM U1153 and PRES Sorbonne Paris City, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2017-211313DOI Listing
July 2018

Considerations for the definition of remission criteria in psoriatic arthritis.

Semin Arthritis Rheum 2018 06 31;47(6):786-796. Epub 2017 Oct 31.

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2017.10.021DOI Listing
June 2018

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

J Rheumatol Suppl 2018 Jun;94:17-25

From the Royal Prince Alfred Hospital Medical Centre, Sydney, Australia; Royal National Hospital for Rheumatic Diseases, Bath, UK; University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA; University of Oxford, Oxford, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada; Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA; Department of Rheumatology, St. Vincents University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; VU Medical Centre, Amsterdam, the Netherlands; IQVIA, Duke University School of Medicine, Durham, North Carolina, USA; School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, Ontario, Canada; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute, and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180142DOI Listing
June 2018

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database.

J Rheumatol Suppl 2018 Jun;94:26-29

From the University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Orthopedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford; Department of Rheumatology, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; Department of Rheumatology, Erasmus Medical Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180132DOI Listing
June 2018

GRAPPA 2017 Project Report.

J Rheumatol Suppl 2018 Jun;94:48-51

From the University of Utah, Salt Lake City, Utah; University of California at San Diego, La Jolla, California; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; New York University School of Medicine, New York; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180139DOI Listing
June 2018

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies.

Ann Rheum Dis 2018 05 26;77(5):e23. Epub 2017 Jul 26.

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2017-212004DOI Listing
May 2018

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).

J Rheumatol 2018 03 15;45(3):367-377. Epub 2017 Dec 15.

From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170429DOI Listing
March 2018

Tofacitinib for Psoriatic Arthritis.

N Engl J Med 2018 02;378(8):775-776

University of Toronto, Toronto, ON, Canada

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1715189DOI Listing
February 2018

CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.

J Rheumatol 2018 01 1;45(1):22-31. Epub 2017 Nov 1.

From the Swedish Medical Center and University of Washington, Seattle, Washington; Janssen Research and Development LLC, Spring House, Pennsylvania, USA; Department of Rheumatology and Connective Tissue Diseases, 2nd University Hospital, CM UMK, Bydgoszcz, Poland; Centro de Reumatologia y Ortopedia, Universidad Metropolitana, Barranquilla, Colombia; Rajavithi Hospital, Bangkok, Thailand; Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand; Institute of Rheumatology, Prague, Czech Republic; Clinical Rheumatology Hospital #25, St. Petersburg, Russia; Head Rheumatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Janssen (China) Research and Development Center, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.161238DOI Listing
January 2018

Real-world burden of comorbidities in US patients with psoriatic arthritis.

RMD Open 2017 28;3(2):e000588. Epub 2017 Dec 28.

Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2017-000588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761305PMC
December 2017

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

J Rheumatol 2017 Oct 1;44(10):1522-1528. Epub 2017 Feb 1.

From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://www.jrheum.org/lookup/doi/10.3899/jrheum.160904
Publisher Site
http://dx.doi.org/10.3899/jrheum.160904DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538953PMC
October 2017

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

N Engl J Med 2017 10;377(16):1537-1550

From the Swedish Medical Center and University of Washington, Seattle (P.M.); Cabrini Health and Monash University, Melbourne, VIC, Australia (S.H.); the Department of Rheumatology, St. Vincent's University Hospital and Conway Institute of Biomolecular and Biomedical Research, University College, Dublin (O.F.); Leiden University Medical Center, Leiden, the Netherlands (D.H.); Brigham and Women's Hospital, Harvard Medical School, Boston (J.F.M.); Centro Multidisciplinario para el Desarrollo Especializado de la Investigación Clínica en Yucatán Sociedad Civil Privada, Merida, Mexico (F.A.-Z.); the Department of Rheumatology and Clinical Immunology, Medical University of Poznan, Poznan, Poland (D.C.); Pfizer, Groton, CT (D.G., C.W., S.M., K.S.K.); and Pfizer, Collegeville, PA (T.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1615975DOI Listing
October 2017

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis.

Rheumatology (Oxford) 2017 08;56(8):1251-1253

Division of Rheumatology, Allergy Immunology, University of California San Diego, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kew390DOI Listing
August 2017

Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.

J Rheumatol 2017 08 15;44(8):1151-1158. Epub 2017 Jun 15.

From the Swedish Medical Center and University of Washington (UW) Medicine, Seattle, Washington; Corrona LLC, Southborough, Massachusetts; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; The University of Texas MD Anderson Cancer Center, Houston, Texas; University of California (UC) at San Diego, La Jolla, California; University of Rochester Medical Center, Rochester; New York University (NYU) School of Medicine, New York, New York; Scott and White Health Plan, Temple, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160963DOI Listing
August 2017

Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment.

Authors:
Philip J Mease

Curr Opin Rheumatol 2017 07;29(4):304-310

Rheumatology Clinical Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000388DOI Listing
July 2017

New pathways of treatment for psoriatic arthritis.

Authors:
Philip Mease

Lancet 2017 06 24;389(10086):2268-2270. Epub 2017 May 24.

Seattle Rheumatology Associates, Swedish Providence-St Joseph Health Systems, Seattle, WA 98122, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(17)31427-7DOI Listing
June 2017

Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.

J Rheumatol 2017 05 15;44(5):599-608. Epub 2017 Mar 15.

From Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine, Seattle, Washington; Department of Medicine, University of Illinois at Chicago; Immunology Clinical Development, AbbVie Inc., Chicago, Illinois, USA; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; Department of Medicine I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160387DOI Listing
May 2017

Proceedings of the GRAPPA 2016 Retreat.

J Rheumatol 2017 05;44(5):668-673

From the Rheumatology Research Unit, Cambridge University Hospitals UK National Health Service (NHS) Foundation Trust, Cambridge; UK National Institute for Health Research Clinical Lecturer, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals NHS Foundation Trust, Bradford, UK; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Krembil Research Institute; Division of Dermatology, Toronto Western Hospital, University of Toronto, Ontario; University of Alberta, Edmonton, Alberta, Canada; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Advisory Services, QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester; New York Medical College, Valhalla; Hofstra Northwell School of Medicine, New Hyde Park, New York, New York; Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Cleveland Clinic, Cleveland, Ohio; University of Utah, Salt Lake City, Utah; University of Southern California, Los Angeles; University of California at San Diego, San Diego, California, USA; Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Division of Rheumatology, University of Cagliari, Cagliari, Italy, Sección Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Federal University of Paraná, Curitiba, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170141DOI Listing
May 2017

International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting.

J Rheumatol 2017 05;44(5):684-685

From the UK National Institute for Health Research (NIHR), Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; PsAZZ Support Group, Bath, UK; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada; Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Cleveland Clinic, Cleveland, Ohio; Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York; University of California at San Diego, San Diego, California, USA; Our Lady's Hospice and Care Services, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170144DOI Listing
May 2017

Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

J Rheumatol 2017 05;44(5):697-700

From Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; University of Utah, Salt Lake City, Utah; QuintilesIMS, Denver, Colorado; Duke University School of Medicine, Durham, North Carolina; Rheumatology Research, Swedish Medical Center; University of Washington School of Medicine, Seattle, Washington; International Dermatology Outcome Measurers, West Granby, Connecticut; Cleveland Clinic, Cleveland, Ohio; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California; Johns Hopkins University School of Medicine; Psoriatic Arthritis Program, Johns Hopkins Arthritis Center, Baltimore, Maryland, USA; VU Medical Centre, Amsterdam, the Netherlands; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital; Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada; Hong Kong Psoriatic Arthritis Association, Hong Kong, China; UK National Institute for Health Research (NIHR), Leeds; Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Royal United Hospital; Royal United Hospital; Pharmacy and Pharmacology, University of Bath, UK; Newman Clinical Research Professor, St. Vincent's University Hospital and University College Dublin; Our Lady's Hospice and Care Services, Dublin, Ireland; Internal Medicine, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170150DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605807PMC
May 2017

GRAPPA 2016 Project Report.

J Rheumatol 2017 05;44(5):706-710

From the UK National Institute for Health Research (NIHR); Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Utah, Salt Lake City, Utah; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.170153DOI Listing
May 2017

Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.

J Rheumatol 2017 02 15;44(2):184-192. Epub 2017 Jan 15.

From the Swedish Medical Center and University of Washington, Seattle, Washington; Amgen Inc., Thousand Oaks, California; Corrona LLC, Southborough, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.160343DOI Listing
February 2017

Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Nat Rev Rheumatol 2016 Dec 10;12(12):743-750. Epub 2016 Nov 10.

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; and at the 2nd Department of Medicine, Hietzing Hospital, Wolkersbergenstraße 1, 1130 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrrheum.2016.183DOI Listing
December 2016

2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria.

Semin Arthritis Rheum 2016 12 30;46(3):319-329. Epub 2016 Aug 30.

National Institute of Nursing Research, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semarthrit.2016.08.012DOI Listing
December 2016